Navigation Links
Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
Date:11/12/2009

THE WOODLANDS, Texas, Nov. 12 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS). Top-line results showed that treatment with one gram of LX1031 four times daily produced a statistically significant improvement in global assessment of relief of IBS pain and discomfort over the four-week dosing period as compared to placebo (p=0.0465). Improvements in global assessment parameters also corresponded with statistically significant improvements in stool consistency. Notably, increased clinical response correlated with a greater reduction in serotonin synthesis as reflected by measures of urinary 5-HIAA, a breakdown product of serotonin.

"Treatment with LX1031 reduced symptoms of IBS in this clinical trial, and holds promise for patients with this disease," said Dr. Brian Zambrowicz, chief scientific officer at Lexicon. "We believe the fact that the clinical benefit was correlated to the reduction in the 5-HIAA biomarker validates our therapeutic strategy of inhibiting TPH as a novel treatment option for patients with IBS. The overall safety and efficacy profile observed to date supports further development of this novel mechanism in IBS."

The Phase 2 clinical trial, which began at the end of December 2008, was a four-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1031 and its effects on symptoms associated with IBS. The study included 155 patients with either diarrhea-predominant IBS or mixed IBS. Two dose levels were evaluated: a 250 mg dose and a 1,000 mg
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Announces Completion of Public Offering of Common Stock
2. Lexicon Announces Pricing of Common Stock in Public Offering
3. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
4. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
6. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
7. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
8. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
9. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
10. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
11. WIFH Atlanta Announces Breakthrough Technique in Laser Hair Removal for Ethnic Skin Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 ... New Guide to that Market, its R&D and Sales Potentials ... assess the future of cancer-treating medicines? Visiongain,s new report gives ... stay ahead. There you discover financial data, R&D trends, opportunities, ... In our analysis you see forecasted sales to 2025 ...
(Date:9/3/2015)... 3,  2015 About Vision Care Products ... considered for this report are Rx lenses, frames, ... are primarily used by consumer for vision correction ... lenses and contact lenses require a prescription for ... cosmetic products that can be purchased like any ...
(Date:9/3/2015)... 3,  2015 About artificial organs ... which are implanted or integrated into individuals ... include artificial heart, kidney, pancreas, and cochlear ... polysulfone, and porous polypropylene), biologics, ceramics, and ... These organs are incorporated with different technologies ...
Breaking Medicine Technology:World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7Vision Care Market in the US 2015-2019 2Global Artificial Organ Market 2015-2019 2
... ZeaVision, LLC announced two internal promotions as the ... its leading EyePromise® nutraceutical products featuring ... to President effective immediately from his previous role of ... appointment to the ZeaVision Executive Board. Founder, ...
... Sept. 1 In recognition of September,s designation as ... Pain Physicians (ASIPP) today announced that it is planning ... life for the approximately 75 million Americans suffering from ... this outreach, ASIPP has developed a consumer section on ...
Cached Medicine Technology:Nutraceutical Leader Announces Internal Promotions of Key Personnel 2American Society of Interventional Pain Physicians (ASIPP) Promotes Patient Education and Outreach Initiatives During National Pain Awareness Month 2
(Date:9/4/2015)... ... September 04, 2015 , ... The USC Eye Institute is ... 9 nationwide by Doximity. Faculty, residents and staff are honored to have contributed ... the quality of our ophthalmology residency program. Our faculty places a high priority on ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in ... in the men’s 400 meters final, with an impressive 44.89 seconds at the 2015 ... Jose, Costa Rica in August 2015. The 44.64 time is a new NACAC Championship ...
(Date:9/4/2015)... ... 2015 , ... FiltersFast.com, the online retail leader in air ... up. FiltersFast.com, will ship all orders over $50.00 for free. Use this ... advantage of this promotion now through September 8, 2015. , Filtersfast.com offers a ...
(Date:9/3/2015)... ... ... While bariatric surgeon Michael Feiz, M.D., F.A.C.S. notes that he advises all ... some patients have been recently asking further questions relating to the best way to ... surgery that should be followed in the days prior to the procedure, Dr. Feiz ...
(Date:9/3/2015)... ... September 03, 2015 , ... William Mattar Law Offices ... Esq. believes this does not stop at any certain demographic or segment of the ... produced one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning will allow ...
Breaking Medicine News(10 mins):Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2
... The National AIDS Fund (NAF) in,Washington, D.C., ... expanding,network of Community Partnerships that support over ... marketing agency, HGX Creative,to spearhead its branding ... National, Community Partnerships and Individual Consumer,Marketing., ...
... Join Forces - Urge Reinvestment of Billions into Medicare,Program, ... of the State of New York, and StateWide Senior ... Schumer to lead the U.S. Senate in,strengthening Medicare by ... premiums, and helping lower income,persons pay for prescription drugs. ...
... and close friend,Lejon Boudreaux, along with world-renowned, ultra-marathoner Dean Karnazes,have ... staging a run,from San Francisco to Los Angeles. The 510-mile ... and end two weeks later on Dec. 14, 2007. At,the ... variety of local,activities. The trip will be chronicled via writings ...
... Healthcare,Foundation (AHF) will provide $100,000 in initial in-kind services ... Initiative announced this morning in Los Angeles and New ... covering the salary of a full-time, citywide coordinator ... -- Spearheading and financing a Public Policy component ...
... little of nutrients that cut their odds for malignancy, study finds ... for women in America,s inner cities to eat in ways that ... Hopkins University study that looked at the dietary habits of 156 ... , The researchers found that about 61 percent of the women ...
... 30 SuperArray Bioscience,Corporation announced today that ... license agreement with The Carnegie Institution. Under ... and,distribute worldwide RNA interference based gene function ... agreement enables SuperArray to offer RNAi-based gene ...
Cached Medicine News:Health News:HGX Selected as Creative Agency for National AIDS Fund New Brand 2Health News:HGX Selected as Creative Agency for National AIDS Fund New Brand 3Health News:Groups Call On Senator Charles Schumer to Lead Senate In Strengthening Medicare 2Health News:Groups Call On Senator Charles Schumer to Lead Senate In Strengthening Medicare 3Health News:Run-in-a-Million Run from San Francisco to Los Angeles to Raise Awareness About AIDS and HIV Testing 2Health News:AIDS Healthcare Foundation's Role in the City of Los Angeles' HIV Testing Initiative 2Health News:Diets May Raise Cancer Risk for Poor, Urban Women 2Health News:SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: